Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C62756
http://purl.obolibrary.org/obo/NCIT_C62756
|
|---|---|
| Preferred Name | Tertomotide |
| Definitions |
A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells. |
|---|---|
| prefLabel | Tertomotide
|
| label | Tertomotide
|
| PDQ_Closed_Trial_Search_ID | 502114
|
| code | C62756
|
| prefixIRI | NCIT:C62756
|
| in_subset | |
| Preferred_Name | Tertomotide
|
| FDA_UNII_Code | 55R7RG342O
|
| Contributing_Source | FDA
|
| Maps_To | Tertomotide
|
| CAS_Registry | 915019-08-8
|
| NCI_Drug_Dictionary_ID | 502114
|
| Legacy Concept Name | GV1001
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 502114
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1831942
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |